Tilton R G, Chang K C, LeJeune W S, Stephan C C, Brock T A, Williamson J R
Department of Cell Biology, Texas Biotechnology Corporation, Houston 77030, USA.
Invest Ophthalmol Vis Sci. 1999 Mar;40(3):689-96.
To explore the effects of brief intravenous (IV) infusion of vascular endothelial growth factor (VEGF) on vascular albumin permeability, blood flow, and vascular conductance (blood flow normalized to arterial blood pressure) in ocular tissues and brain and to assess the role of nitric oxide in mediating these changes.
A quantitative, double-tracer, radiolabeled albumin permeation method was combined with radiolabeled microspheres for assessment of changes in vascular permeability and blood flow, respectively, induced in ocular tissues by IV infusion of recombinant human VEGF165 for 20 minutes (80-450 picomoles/kg body weight). An inhibitor of nitric oxide synthase (NOS), NG-monomethyl-L-arginine (L-NMMA; 50 micromoles/kg body weight infused simultaneously with VEGF), was used to explore the role of nitric oxide in mediating the vascular changes induced by VEGF.
Infusion of VEGF165 in thiopental-anesthetized rats dose-dependently increased 125I albumin permeation in the retina, anterior uvea, and choroid/sclera and in brain, aorta, lung, kidney, small intestine, and peripheral nerve. Mean arterial blood pressure, cardiac output, and stroke volume were decreased only at the highest dose of VEGF, whereas heart rate remained unchanged. Blood flow was increased in the anterior uvea, and vascular conductance was increased in retina, anterior uvea, choroid/sclera, and brain at the highest dose of VEGF. The NOS inhibitor, L-NMMA, blocked VEGF-induced vascular hyperpermeability in all ocular and nonocular tissues, prevented the increase in vascular conductance in all ocular tissues, and blocked the decrease in mean arterial blood pressure, cardiac output, and stroke volume. Infusion of L-NMMA alone decreased vascular conductance in choroid/sclera and kidney, slightly increased mean arterial blood pressure, and in general, did not affect 125I-albumin permeation. (L-NMMA slightly decreased albumin permeation in the retina and increased it in the brain.)
Intravenous infusion of VEGF can acutely impair endothelial cell barrier functional integrity and relax resistance arterioles in ocular tissues and brain through a mechanism involving activation of NOS.
探讨短暂静脉输注血管内皮生长因子(VEGF)对眼组织和脑内血管白蛋白通透性、血流及血管传导率(血流与动脉血压的比值)的影响,并评估一氧化氮在介导这些变化中的作用。
采用定量双示踪放射性标记白蛋白渗透法,并结合放射性标记微球,分别评估静脉输注重组人VEGF165 20分钟(80 - 450皮摩尔/千克体重)对眼组织血管通透性和血流变化的影响。使用一氧化氮合酶(NOS)抑制剂N-甲基-L-精氨酸(L-NMMA;50微摩尔/千克体重,与VEGF同时输注),以探讨一氧化氮在介导VEGF诱导的血管变化中的作用。
在硫喷妥钠麻醉的大鼠中输注VEGF165,可使视网膜、眼前葡萄膜、脉络膜/巩膜以及脑、主动脉、肺、肾、小肠和周围神经中的125I白蛋白渗透呈剂量依赖性增加。仅在最高剂量的VEGF时,平均动脉血压、心输出量和每搏输出量降低,而心率保持不变。在最高剂量的VEGF时,眼前葡萄膜血流增加,视网膜、眼前葡萄膜、脉络膜/巩膜和脑的血管传导率增加。NOS抑制剂L-NMMA可阻断VEGF在所有眼组织和非眼组织中诱导血管通透性增加,阻止所有眼组织中血管传导率增加,并阻断平均动脉血压、心输出量和每搏输出量降低。单独输注L-NMMA可降低脉络膜/巩膜和肾的血管传导率,轻度升高平均动脉血压,总体上不影响1:25I白蛋白渗透。(L-NMMA使视网膜中的白蛋白渗透略有降低,使脑中的白蛋白渗透增加。)
静脉输注VEGF可通过涉及激活NOS的机制,急性损害眼组织和脑内内皮细胞屏障功能完整性并使阻力小动脉舒张。